

DAFTAR PUSTAKA

1. P2PTM Kemenkes RI. Peringatan Hari Thalassemia Sedunia 2017. 8 Mei. 2017.
2. Siddiqui S, Steensma DP, Kyle RA. Thalassemia and Thomas Benton Cooley. *Mayo Clin Proc.* 2017;92(11):e161–2.
3. Galanello R, Origa R. Beta-thalassemia. *Orphanet J Rare Dis.* 2010 May;5(1):11.
4. P2PTM Kemenkes RI. Hari Talasemia Sedunia 2019 : Putuskan Mata Rantai Talasemia Mayor. 8 Mei. 2019.
5. Kementerian Kesehatan Republik Indonesia. Angka Pembawa Sifat Talasemia Tergolong Tinggi. 20 mei. 2019.
6. Muncie HL, Campbell J. Alpha and beta thalassemia. *Am Fam Physician.* 2009 Aug;80(4):339—344.
7. Bayanzay K, Alzoebie L. Reducing the iron burden and improving survival in transfusion-dependent thalassemia patients: current perspectives. *J Blood Med.* 2016;7:159–69.
8. Ragab LA, Hamdy MM, Shaheen IA, Yassin RN. Blood transfusion among thalassemia patients: A single Egyptian center experience. Vol. 7, *Asian Journal of Transfusion Science.* 2013. p. 33–6.
9. Suddock JT, Crookston KP. *Transfusion Reactions.* 2019;
10. Remacha A, Sanz C, Contreras E, De Heredia CD, Grifols JR, Lozano M, et al. Guidelines on haemovigilance of post-transfusional iron overload. *Blood Transfus.* 2013 Jan;11(1):128–39.
11. Abbaspour N, Hurrell R, Kelishadi R. Review on iron and its importance for human health. *J Res Med Sci.* 2014 Feb;19(2):164–74.
12. The Aplastic Anemia and MDS International Foundation. *Iron Chelation.* 2020.
13. Subroto F, Advani N. Gangguan Fungsi Jantung pada Thalassemia Mayor. *Sari Pediatr.* 2016;5(1):12.
14. Sukumaran A, Chang J, Han M, Mintri S, Khaw BA, Kim J. Iron overload

- exacerbates age-Associated cardiac hypertrophy in a mouse model of hemochromatosis. *Sci Rep.* 2017;7(1):1–10.
15. Farmaki K, Tzoumari I, Pappa C, Chouliaras G, Berdoukas V. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. *Br J Haematol.* 2010;148(3):466–75.
 16. Chen B, Li G-F, Shen Y, Huang X, Xu Y-J. Reducing iron accumulation: A potential approach for the prevention and treatment of postmenopausal osteoporosis. *Exp Ther Med.* 2015 Jul;10(1):7–11.
 17. Wahidiyat PA, Liauw F, Sekarsari D, Putriasih SA, Berdoukas V, Pennell DJ. Evaluation of cardiac and hepatic iron overload in thalassemia major patients with T2* magnetic resonance imaging. *Hematology.* 2017 Sep;22(8):501–7.
 18. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart disease and stroke statistics-2015 update: A report from the American Heart Association. *Circulation.* 2015;131(4):e29–39.
 19. Farooq N, Shah S, Basharat A. Association of hypocalcemia with other ironoverload complications in beta thalassemia major patients. *Adv Basic Med Sci.* 2018;2(1):4–7.
 20. Sihombing FDM(9710051). Dampak Pemberian Transfusi Darah Dalam Jangka Panjang Pada Penderita Thalassemia (Studi Pustaka). Undergraduate thesis, Universitas Kristen Maranatha. 2002.
 21. Djoerban Z. Dasar-dasar transfusi darah: Sudoyo Aru, Setiohadi Bambang, Alwi Idrus et al. *Buku Ajar Ilmu Penyakit Dalam, Jilid III, Edisi IV, Pusat Penerbitan Departemen Ilmu Penyakit Dalam FKUI.* 2006;672.
 22. Khoyumthem P, Rachandra K, Goswami S, Lyngdoh L, Sharma A, Singh A. Acute transfusion reactions in a tertiary hospital: A 2-year retrospective study. *J Med Soc.* 2018;32(1):47.
 23. Langhi D, Ubiali EMA, Marques JFC, Verissimo M de A, Loggetto SR, Silvinato A, et al. Guidelines on Beta-thalassaemia major – regular blood transfusion therapy: Associação Brasileira de Hematologia, Hemoterapia e

- Terapia Celular: project guidelines: Associação Médica Brasileira – 2016. *Rev Bras Hematol Hemoter.* 2016;38(4):341–5.
24. Turner T, Hansen A, Kurach J, Acker JP. From Development to Implementation: Adjusting the Hematocrit of Deglycerolized Red Cell Concentrates to Meet Regulatory Standards. *Transfus Med Hemotherapy.* 2017;44(1):30–8.
 25. Sharma RR, Marwaha N. Leukoreduced blood components: Advantages and strategies for its implementation in developing countries. *Asian J Transfus Sci.* 2010 Jan;4(1):3–8.
 26. Basu D, Rajendra Kulkarni. Overview of blood components and their preparation. 2014;58(1):529–37.
 27. D. Joe Chaffin M. Transfusion reactions. November/December. 2012.
 28. Aydinok Y. Thalassemia. *Hematology.* 2012 Apr 1;17(sup1):s28–31.
 29. Andriastuti M, Sari TT, Wahidiyat PA, Putriasih SA. Kebutuhan Transfusi Darah Pasca-Splenektomi pada Thalassemia Mayor. *Sari Pediatr.* 2016;13(4):244.
 30. Bajwa H, Basit H. Thalassemia. *StatPearls.* 2020.
 31. Rachmilewitz EA, Giardina PJ. How I treat thalassemia. *Blood.* 2011 Sep 29;118(13):3479–88.
 32. Firdausu alfu z. Pengaruh Transfusi Darah Terhadap Tingkat Keberhasilan Hidup Pasien Thalassemia. 2020;
 33. IDAI Indonesian Pediatric Society. Mengenal Thalassemia. 2016;
 34. Rujito L. Buku Referensi Talasemia: Genetik Dasar dan Penanganan Terkini. 2020.
 35. Needs T, Gonzalez-Mosquera LF, Lynch DT. Beta Thalassemia. *StatPearls.* 2020.
 36. Taher AT, Saliba AN. Iron overload in thalassemia: different organs at different rates. *Hematology.* 2017 Dec 8;2017(1):265–71.
 37. Fibach E, Rachmilewitz EA. Pathophysiology and treatment of patients with beta-thalassemia – an update. *F1000Research.* 2017 Dec 20;6:2156.
 38. Koochi F, Kazemi T, Miri-Moghaddam E. Cardiac complications and iron

- overload in beta thalassemia major patients—a systematic review and meta-analysis. *Ann Hematol*. 2019 Jun 7;98(6):1323–31.
39. Rojas B, Wahid I. Terapi Transfusi Darah Leukodepleted pada Pasien Thalasemia. *J Hum Care*. 2020;423–35.
 40. Schapkaitz E, Mezgebe MH. The Clinical Significance of Schistocytes: A Prospective Evaluation of the International Council for Standardization in Hematology Schistocyte Guidelines. *Turkish J Haematol Off J Turkish Soc Haematol*. 2017 Mar 1;34(1):59–63.
 41. Viprakasit V, Ekwattanakit S. Clinical Classification, Screening and Diagnosis for Thalassemia. *Hematol Oncol Clin North Am*. 2018 Apr;32(2):193–211.
 42. Rund D. Thalassemia 2016: Modern medicine battles an ancient disease. *Am J Hematol*. 2016 Jan;91(1):15–21.
 43. Caterina Borgna-Pignatti, Gamberini MR. Expert Review of Hematology. *Expert Rev Hematol*. 2011;4(3):353–66.
 44. Karakaş Z, Koç B, Temurhan S, Elgün T, Karaman S, Asker G, et al. Evaluation of Alpha-Thalassemia Mutations in Cases with Hypochromic Microcytic Anemia: The İstanbul Perspective. *Turkish J Hematol*. 2015 Dec 5;32(4):344–50.
 45. Galanello R, Origa R. Beta-thalassemia. *Orphanet J Rare Dis*. 2010;1–15.
 46. Zainuddin V, Abdullah AA, Arif M. Talasemia Beta Hemoglobin E. *Indones J Clin Pathol Med Lab*. 2016;22(1):309.
 47. Kamilah D, Widyaningrum D. Hubungan jenis packed red cell (PRC) yang ditransfusikan dengan reaksi transfusi febrile non haemolytic transfusion reaction (FNHTR). *Intisari Sains Medis*. 2019;10(1):227–31.
 48. Nemeth E. Heparin and β -thalassemia major. *Blood*. 2013 Jul 4;122(1):3–4.
 49. Angastiniotis M, Lobitz S. Thalassemias: An Overview. *Int J Neonatal Screen*. 2019 Mar 20;5(1):16.
 50. Suddarth, Brunner. *Buku Ajar Keperawatan Medikal Bedah*. Jakarta:EGC. 2013.

51. Douet JY, Bujdoso R, Andréoletti O. Leukoreduction and blood-borne vCJD transmission risk. *Curr Opin Hematol*. 2015 Jan;22(1):36–40.
52. Bianchi M, Vaglio S, Pupella S, Marano G, Facco G, Liunbruno GM, et al. Leucoreduction of blood components: An effective way to increase blood safety? *Blood Transfus*. 2016;14(3):214–27.
53. Srihartaty, Siti Y, Soedarmono M, Wahidiyat PA. Perbedaan Penurunan Jumlah Leukosit dan Sitokin pada Packed-Red Cell dengan Metode Buffy-Coat Depleted dan Modifikasi Bed-Side Leucocyte Filtration. *J Indon Med Assoc*. 2014;64(10):447–50.
54. PMI Kota Semarang. *Seputar Donor Darah*. 2020;
55. Ahmadzadeh A, Jalali A, Assar S, Khalilian H, Zandian K, Pedram M. Correlation of renal function with liver iron overload in beta-thalassemia major patients. *Saudi J Kidney Dis Transplant*. 2011;22(3):497–500.
56. Sugiyama S, Jinnouchi H, Kurinami N, Hieshima K, Yoshida A, Jinnouchi K, et al. Impact of Dapagliflozin Therapy on Renal Protection and Kidney Morphology in Patients With Uncontrolled Type 2 Diabetes Mellitus. *J Clin Med Res*. 2018;10(6):446–7.
57. JPAC. *Handbook of Transfusion Medicine*. 2013;
58. Sahu S, Hemlata, Verma A. Adverse events related to blood transfusion. *Indian J Anaesth*. 2014;58(5):543.
59. Davenport RD, Bluth MH. Hemolytic transfusion reactions. In: Rossi's *Principles of Transfusion Medicine*. Chichester, WestSussex: John Wiley & Sons, Ltd.; 2016. p. 642–51.
60. Maharani EA, Noviar G. *Imunohematologi dan Bank Darah*. 2018.
61. Roubinian N. TACO and TRALI: Biology, risk factors, and prevention strategies. *Hematol (United States)*. 2018;2018(1):585–94.
62. Cao A, Galanello R. Beta-thalassemia. *Genet Med*. 2010 Feb 21;12(2):61–76.
63. Rejeki D, Nurhayati N, Supriyanto E. Descriptive Study on Thalassemia. *J Kesehat Masy Nas*. 2012;7(3):139–44.
64. Shah N, Mishra A, Chauhan D, Vora C, Shah N. Study on effect1. Shah N,

- Mishra A, Chauhan D, Vora C, Shah N. Study on effectiveness of transfusion program in thalassemia major patients receiving multiple blood transfusions at a transfusion centre in Western India. *Asian J Transfus Sci* [Internet]. 201. *Asian J Transfus Sci*. 2010;4(2):94.
65. Rejeki DSS, Pradani P, Nurhayati N, Supriyanto S. Model Prediksi Kebutuhan Darah untuk Penderita Talasemia Mayor. *Kesmas Natl Public Heal J*. 2014;295.
66. Yasmeen H, Hasnain S. Epidemiology and risk factors of transfusion transmitted infections in thalassemia major: a multicenter study in Pakistan. *Hematol Transfus Cell Ther*. 2019;41(4):316–23.
67. Safitri R, Ernawaty J, Karim D. Hubungan Kepatuhan Transfusi dan Konsumsi Kelasi Besi terhadap Pertumbuhan Anak dengan Talasemia. *Cybrarians J*. 2015;2(37):1–31.
68. Sawitri H, Husna CA. Karakteristik Pasien Talasemia Mayor di BLUD RSU Cut Meutia Aceh Utara Tahun 2018. *Averrous J Kedokt dan Kesehat Malikussaleh*. 2018;4(2):62.
69. Novita I, Rachmawati. B. Packed Red Cell dengan Delta Hb dan Jumlah Eritrosit Anemia Penyakit Kronis. *J Indones*. 2015;21(3):261–5.
70. Sari TT, Gatot D, Akib AAP, Bardosono S, Hadinegoro SRS, Harahap AR, et al. Immune response of thalassemia major patients in Indonesia with and without splenectomy. *Acta Med Indones*. 2014;46(3):217–25.
71. Dutt N, Sidhu M, Sharma S, Parihar R, Kumar D. Effectiveness of buffy coat leucoreduced packed red blood cells in decreasing febrile non-hemolytic transfusion reactions in thalassemic patients. *Int J Res Med Sci*. 2017;5(5):1756.
72. Agouzal M, Quyou A, Benchekroune K, Khattab M. Characteristics of chelation therapy among beta-thalassemia patients in the North of Morocco. *Clin Rev Opin*. 2010;2(1):1–007.
73. Vichinsky E, Neumayr L, Trimble S, Giardina PJ, Cohen AR, Coates T, et al. Transfusion complications in thalassemia patients: A report from the Centers for Disease Control and Prevention (CME). *Transfusion*.

2014;54(4):972–81.

74. Shanthala Devi A, Gaikholungpou K. Leukodepletion status of blood products and transfusion reactions in thalassemic patients. *J Appl Hematol.* 2014;5(1):29.

